About Us
Part of the global pharmaceutical UBI Group, UBI Pharma consolidates the Group’s established values and builds a strong foundation of technology and production in the manufacture of pharmaceuticals, providing world-class pharmaceutical quality products. We develop innovative products such as non-monoclonal antibodies, novel small molecule drugs, and specialty injectables.
Board of Directors
Director
Dr. Yen-Ning Kuo
- Dr. Yen-Ning Kuo graduated from Tunghai University with a degree in Chemical Engineering. He received his Ph.D. in Chemical Engineering from the University of California, Irvine in 2003 with a scholarship for his doctoral dissertation. Dr. Kuo specializes in chemical process design and biomedical engineering, and has published two papers in relevant fields. Dr. Kuo is currently the COO of the Pharmaceutical Business Center at UBI Pharma. He is responsible for the product line planning, R&D management, marketing, sales and distribution of our human-use pharmaceutical products. Dr. Kuo joined our team in 2005 and began his work at UBI Pharma in the formulation R&D of peptide vaccine products and quality control methods. He was later put in charge of developing our first US-marketed sterile injectable product. During the development, Dr. Kuo reinforced our CMC and quality systems, in order to comply with the U.S. and European standards. In 2013, UBI Pharma successfully obtained the first product license from the U.S. for our sterile injectable product, as well as developed a top-quality regulatory team with experience in U.S. licensure application for pharmaceuticals. From the end of 2010 to 2011, Dr. Kuo joined Jiangsu Meide Biotech, a subsidiary of Vita Gnomics Inc. located in China, where he was responsible for new drug development, product licensing, and strategic alliances in the China market.
UBI Pharma Inc.
No.45, Guangfu N. Rd., Hukou Township, Hsinchu County 303036, Taiwan (R.O.C.)
- Tel：+886-3-5977676
- Fax：+886-3-5981173